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ABSTRACT
There is an increasing demand for easy, high-
throughput (HTP) methods for protein engineering
to support advances in the development of structural
biology, bioinformatics and drug design. Here,
we describe an N- and C-terminal cloning method
utilizing Gateway cloning technology that we have
adopted for chimeric and mutant genes production
as well as domain shuffling. This method involves
only three steps: PCR, in vitro recombination and
transformation. All three processes consist of simple
handling,mixingandincubationsteps.Wehavechar-
acterized this novel HTP method on 96 targets with
.90% success. Here, we also discuss an N- and
C-terminal cloning method for domain shuffling and
a combination of mutation and chimeragenesis with
two types of plasmid vectors.
INTRODUCTION
As structural and in silico biology have advanced, systematic
and robust high-throughput (HTP) methods for protein engin-
eering are required to generate mutants that will allow us to
model and analyze protein function. Production of protein
drugs, including chimeric antibodies, requires a method for
mutagenesis and chimeragenesis. While many methods for
chimeragenesis, such as domain shufﬂing (1,2), have been
developed, the majority utilize complex processes to obtain
the desired protein and are not amenable to HTP automation.
Recently, the cloning systems with in vitro recombination
were developed (3,4) and are amenable to HTP cloning.
Gateway cloning technology, one of such systems, utilizes
the bacteriophage l recombination system in vitro (4). We
characterized this recombination system and succeeded in
introducing N- and C-terminal fragments on each recombina-
tion site by in vitro recombination and cloning in an HTP
manner. This cloning strategy represents an easy HTP method
for site-directed chimeragenesis, protein engineering and
mutagenesis.
In the Gateway cloning system, a fragment carrying attB1
and attB2 recombinationsites on bothendsispreparedby PCR
and introduced into a Donor vector carrying attP1 and attP2
recombination sites by an in vitro recombination reaction
driven by BP clonase. attB1, attB2, attP1 and attP2 sequences
are designed from natural attB and attP sequences, respect-
ively, to obtain speciﬁcity without reduced recombination efﬁ-
ciency. There are two processes in Gateway cloning: the ﬁrst is
intermolecular recombination between a fragment and a plas-
mid at attB1 and attP1 or attB2 and attP2 and the second is
intramolecular recombination. We have developed a novel
strategy for Gateway cloning, named ‘N- and C-term’
(N- and C-terminal) Gateway cloning, in which two independ-
ent fragments, each carrying attB1 or attB2 on their ends, are
combined with a single plasmid containing both attP1 and
attP2 sites. The resulting linear constructs carrying both
N- and C-terminal fragments are circularized and the Gateway
clone is constructed. It was reported that homologous recomb-
ination in Escherichia coli was available for DNA cloning
(5,6). We adopted homologous recombination in E.coli to
circularize a plasmid. This cloning technique offers a rapid,
automatable way to construct chimeric genes and introduce
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MATERIALS AND METHODS
PCR conditions
An aliquot of 20 pmol of primers and 50 ng of template DNA
were used to obtain N- and C-terminal fragments by PCR with
0.5UPfxpolymerase(InvitrogenCorp.,Carlsbad,CA)in25ml
reaction mixture. Cycling parameters for PCR were 15 cycles,
consisting of 1 min at 95 C for denaturing, 2 min at 55 C for
annealing, 3 min at 68 C for extension and 5 min at 68 C for
ﬁnal extension.
BP in vitro recombination
BP recombination was according to the industrial manual with
a half scale. Our condition is as follows: PCR products con-
taining N- and C-terminal fragments (2.5 ml each) and 150 ng
pDONR 201 were combined in a 10 ml reaction mixture con-
taining 1 ml BP clonase (Invitrogen Corp.). It is not necessary
to purify PCR products. The mixture was incubated at 25 C
for 16 h.
Transformation
After the reaction was stopped by proteinase K, 2.5 mlo f
reaction mixture was mixed with 25 ml DH5a competent
cell (Invitrogen Corp.) for transformation. The procedure
was according to the industrial manual. All cells were spread
on Luria–Bertani (LB) plate containing 50 mg/ml Kanamycin
or 25 mg/ml Zeocin.
RESULTS
Experimental design
The general outline of N- and C-terminal Gateway cloning
method for chimeragenesis is illustrated in Figure 1. N- and
C-terminal fragments were obtained by PCR with attB
attached primers and internal gene primers. Internal gene pri-
merswere designed tocreateahomologousregionatthe30 end
of N-terminal and 50 of C-terminal fragments. Symbols a and b
in Figure 1 indicate gene speciﬁc sequences of joining sites of
the 30 end of N- and 50 end of C-terminal fragments, respect-
ively. These fragments were then introduced into a Donor
vector (pDONR) by BP recombination (without any puriﬁca-
tionsteps).E.coliwasthentransformedwiththe linearplasmid
product. The desired, mutated clone was obtained after the
linear plasmid was circularized in the E.coli cell utilizing the
homologous sequences at its ends.
The length of homologous sequences required for
plasmid circularization in E.coli
To address the question of the minimal length of homologous
sequences required for this cloning method, we prepared ﬁve
attB1-N-terminal fragments containing various lengths of
homology when paired with a single attB2-C-terminal. Five
attB1-N-terminal fragments, N930, N940, N959, N998 and
N1053, and one attB2-C-terminal fragment, C709, were
produced by PCR. The length of each attB1-N- and
attB2-C-terminal fragment was 930, 940, 959, 998, 1053
and 709 bp, respectively. Five attB1-N-terminal fragments
had 10, 20, 39, 78 and 133 bp homologous sequences to
attB2-C-terminal fragment at their ends. The design of PCR
and products used for the BP reaction are shown in Figure 2.
Each attB1-N-terminal fragment, attB2-C-terminal frag-
ment and pDONR201 were mixed at a molar ratio of 5:5:1
and BP recombination was carried out. After stopping the
reaction with proteinase K, linear DNA samples were directly
introduced into E.coli DH5a (recA strain). The number of
colonies obtained from 37.5 ng vector DNA and the efﬁciency
of clone recovery for each condition are shown in Table 1.
Even 10 bp homologous region gave 25 colonies. We ana-
lyzed the sequences of the junction region between the N- and
C-terminal fragment to check the ﬁdelity of homologous
recombination in the recA strain. None of the six clones
sequenced from each condition showed unexpected sequences
in the junction region. This indicated that a 10 bp homologous
sequence was sufﬁcientforcorrect homologous recombination
at the ends of the plasmid, although the number of clones
obtained was smaller than with other conditions.
The effect of homologous sequence in the target gene
Some genes contain tandem repeats or short homologous
sequences. We wanted to determine the effect of such
Figure 1. Outline of chimeragenesis with Gateway technology. For details
see text.
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method. To address this question we constructed a clone con-
taining a tandem repeat. We chose a 1732 bp cDNA for the
test gene. This cDNA carried two 26 bp identical sequences,
named ‘rep seq’ sites, and several homologous regions,
whose size and homology were 10–30 bp and 70–90%. The
‘rep seq’ sites are indicated with blue boxes in Figure 3. We
prepared two N-terminal, HN1000 and HN1022, and three
C-terminal fragments, HC836, HC816 and HC474, by PCR.
HN1000andHN1022fragmentscarried‘repseq’sitesat30 end
and 22 bp inside of the end, respectively. Both HC816 and
HC836 had two ‘rep seq’ sites, one proximal and one distal.
The proximal ‘rep seq’ sites of HC816 and HC836 were loc-
ated at 50 end and 22 bp inside of the end, respectively. The
distance between the end and distal ‘rep seq’ site was several
hundred base pairs. HC474 had only a distal ‘rep seq’ site.
We measured the cloning efﬁciency and reliability with
various combinations ofN and C fragments. The combinations
HN1000/HC836, HN1000/HC816 and HN1022/HC816 car-
ried 46, 26 and 48 bp homologous sequence at their ends
and a 26 bp homologous sequence of ‘rep seq’ sites, respect-
ively.Thecombinations HN1000/HC474 andHN1022/HC474
had no end homologous sequence but a 26 bp homologous
sequence of ‘rep seq’ sites. We randomly selected 16 colonies
from each experiment for characterization. The number of
colonies obtained from 37.5 ng vector DNA and the ratio
of correct clones are shown in Table 2. Sequence analysis
of the resultant clones from the combinations HN1000/
HC474 and HN1022/HC474 showed that recombination
had occurred between ‘rep seq’ sites at the end of the
N-terminal fragment and the mid region of the C-terminal
fragment. The ratios of homologous recombination between
two ‘rep seq’ sites obtained by the combinations HN1000/
HC474 and HN1022/HC474 were 12/16 and 8/16, respect-
ively. The remaining clones in these experiments showed
recombination between the other homologous regions.
The combination HN1000/HC816, which had a 26 bp
homologous region at both ends of N- and C-terminal frag-
ments, was tested for efﬁciency to produce speciﬁc designed
clones by end recombination. The ratio of designed clone
Figure 2. Preparationof N- and C-terminalfragmentswith differentlengths of
homologous sequences on the ends. Five N-terminal and one C-terminal frag-
ments were prepared by PCR. The combinations of N- and C-terminal frag-
mentsgave10,20,39,78and133bphomologoussequencesontheendsofeach
fragment.
Table 1. Relation between the length of homologous region and efficiency of
cloning
Length of homologous
region
10 bp 20 bp 39 bp 78 bp 133 bp
Number of colonies 25 110 334 367 406
Rate of right clone 6/6 6/6 6/6 6/6 6/6
Figure 3. Preparation of N- and C-terminal fragments from a template gene carrying identical sequences. The target gene had two identical sequences named
‘repseq’indicatedbyblueboxes.TwoN-terminalfragments,HN1000andHN1022,andthreeC-terminalfragments,HC836,HC816andHC474,werepreparedby
PCR. HC836 and HC816 had two ‘rep seq’ on their 50 ends and inside of the fragments. The other fragments had only one rep seq’.
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recombination between ‘rep seq’ of the N-terminal fragment
and the mid C-terminal fragment was 5/16. The ratio of
the recombination among other homologous sequence was
also 5/16. The combinations HN1000/HC836 and HN1022/
HC816 showed 46 and 48 bp homologous region at the ends,
respectively, and the frequency of the end recombination of
these combinations was very high at 15/16 and 14/16, respect-
ively. These results suggested that the combination of N- and
C-terminal fragments with long, ( 40–50 bp), homologous
regions at their ends produced the desired clones with high
reliability even if the gene had short homologous regions, such
as  30 bp identical sequence.
The amount of N- and C-terminal fragments required
for cloning
We analyzed the range and suitable amount of DNA fragments
for cloning. We selected the combination N959/C709, whose
length of end homologous region was 39 bp, for this analysis.
We measured colony forming ability and reliability of cloning
with a combination of different molar ratios of fragments
and 150 ng pDONR vector, from 1/32:1/32:1 to 32:32:1.
The amount of PCR fragment was from 1.56 to 1636 ng.
After the BP reaction, we introduced linear plasmid, which
had 37.5 ng vector DNA, into E.coli and counted the number
of colonies. We selected eight colonies from each experiment
and sequence analyzed these clones. The results are summar-
ized in Table 3. For cloning of this 1.5 kb gene, the optimal
ratio of fragments and a vector was 2:1. Using this condition,
425 colonies were obtained with all eight sequenced clones
having the desired sequence. This experiment showed that
the desired clone was obtained with high reliability using a
wide variation in the relative quantity. Even when using <2n g
of insert fragment, 3% of vector DNA gave the right clone
although the rate of the right clone was only 1/8.
HTPGatewaycloningwithN-andC-terminalfragments
HTP methods require simple procedures, which will work
for a wide range of amount of substrates to reliably complete
each reaction. The results of all experiments described above
showed that the N- and C-terminal cloning method using the
Gateway system incorporate not only easy handling proced-
ures and high cloning efﬁciency but also that the reliability of
this method was very high when the ends of N- and C-terminal
fragments were designed to carry 40 bp or longer homologous
sequences for recombination in E.coli. These results demon-
strate that our N- and C-terminal cloning method was suitable
for HTP cloning and chimeragenesis.
We measured the success rate of this method for HTP
handling with 96 target genes. These samples were randomly
chosen from human full-length cDNA library. The sizes of
their open reading fragment were from 603 to3381 bp. Among
these clones, 37 clones had 603–1000 bp, 39 clones had 1001–
2000 bp and 20 clones had more than 2000 bp long target
regions for cloning. The primers for ampliﬁcation of N- and
C-terminal fragments were designed to produce 30–60% full-
lengthfragments containing40 bp end homologous sequences.
Ninety-six combinations of N- and C-terminal fragments were
mixed with 150 ng pDNOR201 vector and in vitro BP recomb-
ination reactions were carried out. One-fourth of each reaction
mixture was used to transform competent E.coli and the cells
were plated on LB containing 50 mg/ml of Kanamycin. After
the colonies were counted, four colonies from each plate were
randomly selected, and the length of inserts and their
sequences were analyzed. The ampliﬁed N- and C-terminal
fragments and inserts of clones are shown in Figure 4a.
Cloning efﬁciency and rates of the desired clones are illus-
trated in Figure 4b and c, respectively. No colonies were
obtained from ﬁve targets, four of which did not produce
N- or C-terminal fragments by PCR (indicated by green
dots in Figure 4a). A total of 66 out of 96 reactions (69%)
gave only correct clones and 16 out of 96 (17%) gave only one
wrongcloneswhenfourclonesfromeachpointwereanalyzed.
More than 85% (82 out of 96) gave the desired clones with
high reliability. Cloning failed completely for only 7 out of 96
targets using this system equating to a 93% success rate when
four clones from each reaction were checked.
Introduction of mutations
The N- and C-terminal Gateway cloning method was also
applicable to site-directed mutagenesis, introducing point
mutation, deletion, insertion or substitution at any position
in the gene according to the primer design. When two priming
Table 2. Relation between the length of homologous region and cloning efficiency for the target containing tandem repeats
Combination of fragments NH1000 · HC474 NH1022 · HC474 NH1000 · HC816 NH1000 · HC836 NH1022 · HC816
End homologous region (bp) 0 0 26 46 48
Number of colonies 132 37 124 76 195
Recombination between the end of N-terminal
and C-terminal fragments
– – 6/16 15/16 14/16
Recombination between the end of N-terminal
fragment and inside ‘rep seq’ of
C-terminal fragment
12/16 8/16 5/16 1/16 1/16
Others 4/16 8/16 5/16 0/16 1/16
Table 3. Relation between the amount of N- and C-terminal fragments and
cloning efficiency
Ratio between
vector and
fragment
1/32 1/16 1/8 1/4 1/2 1/1 2 4 8 16 32
Number of
colonies
15 14 58 177 203 362 425 397 273 157 77
Rate of right
clone
1/8 6/8 6/8 5/8 7/8 6/8 8/8 8/8 8/8 7/8 7/8
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N- and C-terminal method was a deletion clone that lacked
the sequence between the two priming sites. Using mutated
primer and primers containing additional sequences at the 50
end of oligo, DNA produced a point mutant and insertion
clone, respectively. The combination of deletion and insertion
procedures gave a substitution clone. We constructed a point
mutation, 120 bp deletion, 80 bp insertion and 80 bp substi-
tution clones with 1.5 kb cDNA and evaluated these mutant
clones by sequencing. We checked six clones of each mutant,
and all clones showed the designed sequence in the whole
region of the gene.
DISCUSSION
There is an increasing requirement for HTP protein engineer-
ing methods to meet the demands of drug discovery and the
development of chimeric antibodies for human healthcare. In
an attempt to meet this demand, the Multisite Gateway tech-
nology was reported (7,8). This system assembled multiple
DNA sequences and makes domain shufﬂing easily. However,
this system required the recombination sequences, an att site,
between assembled DNA segments and added several amino
acid residues between domains. To improve this point, we
developed an HTP N- and C-terminal cloning method using
the Gateway system. The Gateway system uses in vitro site-
speciﬁc recombination generating clones without requirement
for restriction enzyme digestion and ligation. BP reactions are
highly efﬁcient and we obtained desired clones using <10 pg
PCR fragments for 1 kb targets (data not shown).
HTP methods for cloning should allow the handling of
numerous samples and generate the desired clones in a short
period. We demonstrated that our N- and C-terminal cloning
system showed not only reliability, ease of production and
screening, but also ability to utilize a wide range of substrates,
and that high success rate was shown when 96 samples were
handled. Our N- and C-terminal cloning method contained
only three steps: PCR, BP in vitro recombination and transfor-
mation. The simplicity of the PCR process (mixing primer set,
template DNA, reaction solution and enzyme) facilitates
establishment of this HTP method. The BP reaction requires
simple mixing of PCR products, pDONR vector and reaction
mixture without any puriﬁcation step. The transformation step
also requires only mixing of samples after the BP reaction and
competent cells without any puriﬁcation step. Therefore, all
steps can easily be automated.
We usually use 50–100 ng template plasmid DNA for
15 cycles PCR with Pfx polymerase (Invitrogen Corp.) and
obtained 10–100 ng PCR fragments. In the case of our test
gene in this paper, which was 1.5 kb, we obtained the desired
clones efﬁciently with 3 ng to 1.6 mg PCR fragments. Fifteen
cycles of PCR with high ﬁdelity PCR enzyme, such as Pfx
or KOD, gave 1/10 kb error rate from our analysis of more
than 10 000 clones. The error rate of synthetic oligo DNA for
cloning primer (synthesized by Invitrogen Corp., Japan) was
1/2000 bp according to the analysis of 2500 clones. The test
experiment for the HTP method described in this paper failed
to gain colonies against ﬁve templates. We characterized 364
clones, 91 target genes · 4 sub-clones, and observed 42 incor-
rect clones. This showed that accuracy was 88.5%. Only 2 out
(a)
(b)
(c)
Figure 4. Summary of HTP N- and C-terminal cloning. (a) Gel showed N-
and C-terminal fragments used for cloning and inserted fragments of clones.
Symbols N and C indicate N- and C-terminal fragments, and I indicates insert
fragments amplified by PCR. The dots indicate the position of missing
fragments; green for N- or C-terminal; and yellow for right insert fragments.
(b and c) Number of obtained colonies and the rate of right clone.
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other showed different sizes of inserts or vector background.
Such size differences were easily observed by colony PCR and
gel electrophoresis. This suggested that the accuracy of this
HTP method was very high and colony PCR was sufﬁcient for
selection ofdesired clones.Allofourresultsdemonstratedthat
the N- and C-terminal cloning method described here was
suitable for HTP chimeragenesis and site-speciﬁc mutagen-
esis.
Since two types of pDONR vector carrying different anti-
biotics resistant genes, Kanamycin and Zeocin, exist, serial
N- and C-terminal cloning for chimeragenesis and domain
shufﬂing are possible. The length of insertion and substitution
depends on the length of reliable oligo primers. Reasonable
length for the reliable primers is 80mer. This length creates an
80 bp insertion because 40 bp is required for homologous
recombination in E.coli and 20 bp is used as the priming
site for PCR. We established one-step adapter PCR, using
four primers in one tube PCR, as described previously (9).
This method allowed a 200 bp insertion. Serial cloning also
gives longer insertion and substitution.
Translocation of chromosomes produces chimeric proteins
underlying many diseases, including hematological malignan-
cies and solid tumors. Mitelman et al. (10) reported that
209 fusion genes on hematological malignancies and 271
fusion genes on solid tumors. The characterization of chimeric
proteins is important to understand the mechanism of such
diseases. However, one of the biggest problems is the difﬁ-
culty to obtain full-length cDNA clones with fusion from
patents. Recently, several projects produced huge number
of human full-length cDNAs (11,12), which covered most
genes of human. The method presented here can create all
chimeric clones using the established full-length cDNAs
and will open the cyclopedic study on functional analyses
of fusion proteins in cancer.
In this paper, we introduced the method for protein engin-
eering included chimera protein production. Our method was
for assembling two DNA fragments and constructing plasmids
by HTP way. This method allowed introducing any kinds of
sequences, such as regulatory sequences, localization signals
and control elements at any place of genes and had the wide
application. We believe that this method helps the works of
many research ﬁelds.
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